Shares of Thermo Fisher Scientific Inc. (NYSE:TMO – Get Free Report) have received an average recommendation of “Moderate Buy” from the twenty-two analysts that are currently covering the company, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $649.33.
A number of analysts recently issued reports on the company. UBS Group raised Thermo Fisher Scientific to a “strong-buy” rating in a report on Monday, September 16th. Barclays reduced their price objective on shares of Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating for the company in a research note on Wednesday. Sanford C. Bernstein lowered their target price on shares of Thermo Fisher Scientific from $625.00 to $620.00 and set a “market perform” rating on the stock in a research note on Thursday. Morgan Stanley upped their price target on shares of Thermo Fisher Scientific from $655.00 to $680.00 and gave the stock an “overweight” rating in a report on Friday, September 20th. Finally, Robert W. Baird dropped their price objective on Thermo Fisher Scientific from $632.00 to $622.00 and set an “outperform” rating for the company in a research note on Thursday.
Read Our Latest Stock Analysis on Thermo Fisher Scientific
Insider Buying and Selling at Thermo Fisher Scientific
Hedge Funds Weigh In On Thermo Fisher Scientific
Hedge funds and other institutional investors have recently modified their holdings of the stock. Signature Resources Capital Management LLC lifted its stake in shares of Thermo Fisher Scientific by 318.2% in the 2nd quarter. Signature Resources Capital Management LLC now owns 46 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 35 shares during the period. New Millennium Group LLC purchased a new position in Thermo Fisher Scientific during the second quarter valued at $29,000. Stephens Consulting LLC boosted its holdings in shares of Thermo Fisher Scientific by 116.0% during the 2nd quarter. Stephens Consulting LLC now owns 54 shares of the medical research company’s stock valued at $30,000 after buying an additional 29 shares in the last quarter. Headlands Technologies LLC purchased a new stake in shares of Thermo Fisher Scientific in the 1st quarter worth about $32,000. Finally, Bank & Trust Co purchased a new position in Thermo Fisher Scientific during the 2nd quarter valued at about $33,000. Hedge funds and other institutional investors own 89.23% of the company’s stock.
Thermo Fisher Scientific Price Performance
Shares of NYSE:TMO opened at $554.38 on Friday. The firm has a market capitalization of $211.77 billion, a PE ratio of 34.39, a P/E/G ratio of 3.75 and a beta of 0.77. The company has a quick ratio of 1.37, a current ratio of 1.72 and a debt-to-equity ratio of 0.64. The company has a 50-day moving average price of $606.12 and a two-hundred day moving average price of $584.21. Thermo Fisher Scientific has a twelve month low of $420.21 and a twelve month high of $627.88.
Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last released its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share for the quarter, beating analysts’ consensus estimates of $5.25 by $0.03. The business had revenue of $10.60 billion during the quarter, compared to analyst estimates of $10.63 billion. Thermo Fisher Scientific had a net margin of 14.69% and a return on equity of 18.22%. Thermo Fisher Scientific’s revenue was up .2% compared to the same quarter last year. During the same period in the previous year, the business earned $5.69 EPS. Equities analysts forecast that Thermo Fisher Scientific will post 21.72 EPS for the current year.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Featured Articles
- Five stocks we like better than Thermo Fisher Scientific
- Consumer Staples Stocks, Explained
- Texas Roadhouse Stock Steering for New Highs This Year
- 3 Best Fintech Stocks for a Portfolio Boost
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.